{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T07:18:55Z","timestamp":1788160735423,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08566-4","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:35:04Z","timestamp":1783528504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging preclinical development and clinical manufacturing: a translational GMP-Platform for lentiviral vector production in academic CAR T-Cell therapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Maribel","family":"Lara-Chica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Arribas-Arribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Mu\u00f1oz-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Dolores de la Rosa-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Montiel-Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Bermejo-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"M\u00e1rquez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Hern\u00e1ndez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Guijarro-Albaladejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Sierro-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"P\u00e9rez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Carmona-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3041-9860","authenticated-orcid":false,"given":"Estefan\u00eda","family":"Garc\u00eda-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"8566_CR1","unstructured":"Anti-BCMA chimeric antigen receptor (CARTemis-1) T-lymphocyte therapy in the treatment of patients with multiple myeloma in relapse after allogeneic transplant: EGFR expression as a control mechanism of treatment-derived. EuCT number 2022-503063-15-00 com. Clin Trials EU. Published 2024. https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en%26EUCT=2022-503063-15-00."},{"key":"8566_CR2","unstructured":"European Commission. Guidelines on Good manufacturing Practice specific to Advanced therapy medicinal products. 2017. 4(November):1\u201332. https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol-4\/2017_11_22_guidelines_gmp_for_atmps.pdf%0Ahttps:\/\/ec.europa.eu\/commission\/index_en."},{"key":"8566_CR3","unstructured":"ICH IC for H. ICH Guideline Q5A(R2) on viral safety evaluation of Biotechnology products derived from cell lines of human or animal origin. 2023."},{"key":"8566_CR4","unstructured":"FDA (Food and Drug Administration). Virology test Methods. Unites States Pharmacopeia, Edition USP-NF 2024.; 2024."},{"key":"8566_CR5","unstructured":"American Type Culture Collection (ATCC). ATCC Cell Culture Technical Resource. 2011. http:\/\/www.rktech.hu\/dokumentaciok\/LGC\/ATCC_Cell_Culture_Technical_Resource_catalogue.pdf."},{"key":"8566_CR6","unstructured":"FDA. Guidance for industry cell characterization and qualification of cell substrates and other biological materials used in the production of viral Vaccines for infectious disease indications. 2010;1\u201350. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Vaccines\/UCM202439.pdf."},{"key":"8566_CR7","unstructured":"European Medicines Agency. Part II: basic requirements for active substances used as starting materials. Good Manufacturing Practice Medicinal Products for Human and Veterinary Use. 2014. https:\/\/health.ec.europa.eu\/document\/download\/bd537ccf-9271-4230-bca1-2d8cb655fd83_en?filename=2014-08_gmp_part1.pdf."},{"key":"8566_CR8","unstructured":"EDQM ED for the Q of M. European Pharmacopoeia. Microbiological control of cell-based preparations.\u201d in. 11.2th edition. Volume 2 6.27. \u201c2024."},{"key":"8566_CR9","unstructured":"EDQM ED for the Q of M. European Pharmacopoeia. In: Sterility. Vol 11.2. 11th Edition. Volume 2.6.1. 2022."},{"key":"8566_CR10","unstructured":"EDQM ED for the Q of M. European Pharmacopoeia. 11th edition. Volume 2.7.1 \u201cImmunochemical methods\u201d Strasbourg, France; in: European Directorate for the Quality of Medicines (EDQM); 2008."},{"key":"8566_CR11","unstructured":"(EDQM) ED for the Q of M. European Pharmacopoeia. In: Bacterial endotoxins. 10th edition. Volume 2.6.14 Strasbourg, France: European Directorate for the Quality of Medicines (EDQM); 2020. p. 209\u201313 (ISBN 978-92-871-8921-9."},{"key":"8566_CR12","unstructured":". https:\/\/www.aatbio.com\/tools\/four-parameter-logistic-4pl-curve-regression-online-calculator ATT Bioquest\u00ae."},{"key":"8566_CR13","unstructured":"European Medicines Agency (EMA). Guideline on development and manufacture of lentiviral vectors. 2005."},{"issue":"1","key":"8566_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s13402-024-00984-0","volume":"48","author":"Sierro-Mart\u00ednez","year":"2025","unstructured":"Sierro-Mart\u00ednez, Escamilla-G\u00f3mez, P\u00e9rez-Ortega, Guijarro-Albaladejo B, Hern\u00e1ndez-D\u00edaz P, de la Rosa-Garrido M, et al. Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features. Published online 2024. Cellular Oncol. 2025;48(1):219\u201337. https:\/\/doi.org\/10.1007\/s13402-024-00984-0.","journal-title":"Cellular Oncol"},{"issue":"2","key":"8566_CR15","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3324\/haematol.2022.281339","volume":"108","author":"E Garc\u00eda-Guerrero","year":"2022","unstructured":"Garc\u00eda-Guerrero E, Rodr\u00edguez-Lobato LG, Sierro-Mart\u00ednez B, Danhof S, Bates S, Frenz S, et al. All-trans retinoic acid works synergistically with the \u03b3-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells. Haematologica. 2022;108(2):568\u201380. https:\/\/doi.org\/10.3324\/haematol.2022.281339.","journal-title":"Haematologica"},{"issue":"1","key":"8566_CR16","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1186\/s12967-025-06899-0","volume":"23","author":"B Sierro-Mart\u00ednez","year":"2025","unstructured":"Sierro-Mart\u00ednez B, Guijarro-Albaladejo B, Fern\u00e1ndez-Cisnal R, Rodr\u00edguez-Gil A, Hern\u00e1ndez-D\u00edaz P, de la Rosa-Garrido M, et al. Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies. J Transl Med. 2025;23(1):0. https:\/\/doi.org\/10.1186\/s12967-025-06899-0.","journal-title":"J Transl Med"},{"key":"8566_CR17","unstructured":"EDQM ED for the Q of M. European Pharmacopoeia. In: 5.34. Additional information on gene therapy medicinal products for human use. Vol. 11.8. 2025."},{"key":"8566_CR18","doi-asserted-by":"crossref","unstructured":"Doherty Kts L, GML. DNA fingerptinting as a quality control marker for genetic stability of production cells. Qual Biotech Ltd, Glas UK. Published online 1994.","DOI":"10.1016\/B978-0-7506-1845-8.50017-X"},{"issue":"Bs 5750","key":"8566_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/978-3-0348-7312-3_27","volume":"58","author":"GN Stacey","year":"1991","unstructured":"Stacey GN, Bolton BJ, Doyle A. The quality control of cell banks using DNA fingerprinting. EXS. 1991;58(Bs 5750):361\u201370. https:\/\/doi.org\/10.1007\/978-3-0348-7312-3_27.","journal-title":"EXS"},{"issue":"6375","key":"8566_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/357261a0","volume":"357","author":"GN Stacey","year":"1992","unstructured":"Stacey GN, Bolton BJ, Doyle A. DNA fingerprinting transforms the art of cell authentication. Nature. 1992;357(6375):261\u201362. https:\/\/doi.org\/10.1038\/357261a0.","journal-title":"Nature"},{"key":"8566_CR21","doi-asserted-by":"publisher","unstructured":"ICH IC for H. ICH topic Q 5 A \u201cquality of biotechnological products: viral safety evaluation of Biotechnology products derived from cell lines of human or animal origin step 5 NOTE\u201d. ICH Qual Guidel. Published online 1997. doi: https:\/\/doi.org\/10.1002\/9781118971147.ch10.","DOI":"10.1002\/9781118971147.ch10"},{"key":"8566_CR22","unstructured":"World Health Organization W. WHO study group on cell substrates for production of biologicals. 2007. https:\/\/cdn.who.int\/media\/docs\/default-source\/biologicals\/cell-substrates\/cells.final.mtgrep.ik.26_sep_07.pdf?sfvrsn=3db7d37a_3%26download=true."},{"issue":"3","key":"8566_CR23","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/bit.22304","volume":"103","author":"X Wang","year":"2009","unstructured":"Wang X, Hunter AK, Mozier NM. Host cell proteins in biologics development: identification, quantitation and risk assessment. Biotech & Bioeng. 2009;103(3):446\u201358. https:\/\/doi.org\/10.1002\/bit.22304.","journal-title":"Biotech & Bioeng"},{"key":"8566_CR24","unstructured":"EDQM ED for the Q of M. European Pharmacopoeia. In: Mycoplasmas. 11Th Edition. Volume 2.6.7. 2023."},{"key":"8566_CR25","unstructured":"Scheme P inspection cooperation. PI 007\u20136 recommendation on the validation aseptic processes. PIC\/S Secretariat. Published 2011. https:\/\/picscheme.org\/docview\/3446."},{"key":"8566_CR26","doi-asserted-by":"publisher","unstructured":"Perpi\u00f1\u00e1 U, Herranz C, Mart\u00edn-Ib\u00e1\u00f1ez R, Boronat A, Chiappe F, Monforte V, et al. Cell banking of HEK293T cell line for clinical-grade lentiviral particles manufacturing. Transl Med Commun. 2020;5(1). https:\/\/doi.org\/10.1186\/s41231-020-00075-w.","DOI":"10.1186\/s41231-020-00075-w"},{"issue":"December","key":"8566_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.omtm.2020.10.009","volume":"19","author":"M Soldi","year":"2020","unstructured":"Soldi M, Sergi Sergi L, Unali G, Kerzel T, Cuccovillo I, Capasso P, et al. Laboratory-scale lentiviral vector production and purification for enhanced ex vivo and in vivo genetic engineering. Mol Ther Methods Clin Dev. 2020;19(December):411\u201325. https:\/\/doi.org\/10.1016\/j.omtm.2020.10.009.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"8566_CR28","first-page":"32","volume":"10","author":"LJ Ausubel","year":"2012","unstructured":"Ausubel LJ, Hall C, Sharma A, et al. Production of CGMP-Grade lentiviral vectors. Bioprocess Int. 2012;10(2):32\u201343. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3624763\/pdf\/nihms412728.pdf.","journal-title":"Bioprocess Int"},{"issue":"March","key":"8566_CR29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.omtm.2018.11.010","volume":"12","author":"M Castella","year":"2019","unstructured":"Castella M, Boronat A, Mart\u00edn-Ib\u00e1\u00f1ez R, Rodr\u00edguez V, Su\u00f1\u00e9 G, Caballero M, et al. Development of a Novel anti-CD19 chimeric antigen receptor: a paradigm for an affordable CAR T cell production at academic institutions. Mol Ther Methods Clin Dev. 2019;12(March):134\u201344. https:\/\/doi.org\/10.1016\/j.omtm.2018.11.010.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"8566_CR30","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1080\/21655979.2021.1931644","volume":"12","author":"QL Tang","year":"2021","unstructured":"Tang QL, Gu LX, Xu Y, Liao XH, Zhou Y, Zhang TC. Establishing functional lentiviral vector production in a stirred bioreactor for CAR-T cell therapy. Bioengineered. 2021;12(1):2095\u2013105. https:\/\/doi.org\/10.1080\/21655979.2021.1931644.","journal-title":"Bioengineered"},{"issue":"1","key":"8566_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jviromet.2011.06.019","volume":"177","author":"AR Cooper","year":"2011","unstructured":"Cooper AR, Patel S, Senadheera S, Plath K, Kohn DB, Hollis RP. Highly efficient large-scale lentiviral vector concentration by tandem tangential flow filtration. J Virol Methods. 2011;177(1):1\u20139. https:\/\/doi.org\/10.1016\/j.jviromet.2011.06.019.","journal-title":"J Virol Methods"},{"issue":"2","key":"8566_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14440\/jbm.2018.236","volume":"5","author":"N Rout-Pitt","year":"2018","unstructured":"Rout-Pitt N, McCarron A, McIntyre C, Parsons D, Donnelley M. Large-scale production of lentiviral vectors using multilayer cell factories. JBM. 2018;5(2):1. https:\/\/doi.org\/10.14440\/jbm.2018.236.","journal-title":"JBM"},{"issue":"June","key":"8566_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.omtm.2019.11.011","volume":"17","author":"M Bauler","year":"2020","unstructured":"Bauler M, Roberts JK, Wu CC, Fan B, Ferrara F, Yip BH, et al. Production of lentiviral vectors using suspension cells grown in Serum-free media. Mol Ther Methods Clin Dev. 2020;17(June):58\u201368. https:\/\/doi.org\/10.1016\/j.omtm.2019.11.011.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"8566_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-23593-y","volume":"8","author":"HA Tom\u00e1s","year":"2018","unstructured":"Tom\u00e1s HA, Rodrigues AF, Carrondo MJT, Coroadinha AS. LentiPro26: novel stable cell lines for constitutive lentiviral vector production. Sci Rep. 2018;8(1):1\u201311. https:\/\/doi.org\/10.1038\/s41598-018-23593-y.","journal-title":"Sci Rep"},{"issue":"1","key":"8566_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/gt.2017.91","volume":"25","author":"AJ Valkama","year":"2018","unstructured":"Valkama AJ, Leinonen HM, Lipponen EM, Turkki V, Malinen J, Heikura T, et al. Optimization of lentiviral vector production for scale-up in fi xed-bed bioreactor. Gene Ther. 2018;25(1):39\u201346. https:\/\/doi.org\/10.1038\/gt.2017.91.","journal-title":"Gene Ther"},{"key":"8566_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.omtm.2023.06.011","volume":"30","author":"CR Fiol","year":"2023","unstructured":"Fiol CR, Collignon M-L, Welsh J, Rafiq QA. Optimizing and developing a scalable, chemically defined, animal component-free lentiviral vector production process in a fixed-bed bioreactor. Mol Ther Methods Clin Dev. 2023;30:221\u201334. https:\/\/doi.org\/10.1016\/j.omtm.2023.06.011.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"June","key":"8566_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fbioe.2022.887716","volume":"10","author":"MY Tran","year":"2022","unstructured":"Tran MY, Kamen AA. Production of lentiviral vectors using a HEK-293 producer cell line and Advanced perfusion processing. Front Bioeng Biotechnol. 2022;10(June):1\u201312. https:\/\/doi.org\/10.3389\/fbioe.2022.887716.","journal-title":"Front Bioeng Biotechnol"},{"issue":"September","key":"8566_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fbioe.2025.1648028","volume":"13","author":"P Singh","year":"2025","unstructured":"Singh P, Lal NI, Terrao M, Schwingal S, Biserni M, Aeschimann F, et al. Enhancing lentiviral production for WAS gene therapy: a comparative analysis of stable producer cell lines evaluating flatware system and adherent bioreactors in perfusion mode. Front Bioeng Biotechnol. 2025;13(September):1\u201323. https:\/\/doi.org\/10.3389\/fbioe.2025.1648028.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"8566_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12896-018-0419-0","volume":"18","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Qiu S, Zhang X, Chen W. Optimized DNA electroporation for primary human T cell engineering. BMC Biotechnol. 2018;18(1):1\u20139. https:\/\/doi.org\/10.1186\/s12896-018-0419-0.","journal-title":"BMC Biotechnol"},{"key":"8566_CR40","doi-asserted-by":"publisher","unstructured":"Harris E, Elmer JJ. Optimization of electroporation and other non-viral gene delivery strategies for T cells. Biotechnol Prog. 2021;37(1). https:\/\/doi.org\/10.1002\/btpr.3066.","DOI":"10.1002\/btpr.3066"},{"key":"8566_CR41","doi-asserted-by":"publisher","unstructured":"Sun N, Wang C, Edwards W, Wang Y, Lu XL, Gu C, et al. Nanoneedle-based electroporation for efficient manufacturing of human primary chimeric antigen receptor regulatory T-Cells. Adv Sci. 2025;12(21). https:\/\/doi.org\/10.1002\/advs.202416066.","DOI":"10.1002\/advs.202416066"},{"issue":"17","key":"8566_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/smll.202410975","volume":"21","author":"J Lim","year":"2025","unstructured":"Lim J, Oh D, Cheng M, Chintapula U, Liu S, Reynolds D, et al. Enhancing chimeric antigen receptor T-Cell generation via microfluidic mechanoporation and lipid nanoparticles. Small. 2025;21(17):1\u201313. https:\/\/doi.org\/10.1002\/smll.202410975.","journal-title":"Small"},{"issue":"C","key":"8566_CR43","doi-asserted-by":"publisher","first-page":"100375","DOI":"10.1016\/j.iotech.2023.100375","volume":"18","author":"H Balke-Want","year":"2023","unstructured":"Balke-Want H, Keerthi V, Cadinanos-Garai A, Fowler C, Gkitsas N, Brown AK, et al. Non-viral chimeric antigen receptor (CAR) T cells going viral. Immuno-Oncol Technol. 2023;18(C):100375. https:\/\/doi.org\/10.1016\/j.iotech.2023.100375.","journal-title":"Immuno-Oncol Technol"},{"issue":"June","key":"8566_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.867013","volume":"13","author":"A Moretti","year":"2022","unstructured":"Moretti A, Ponzo M, Nicolette CA, Tcherepanova IY, Biondi A, Magnani CF. The past, present, and future of non-viral CAR T cells. Front Immunol. 2022;13(June):1\u201325. https:\/\/doi.org\/10.3389\/fimmu.2022.867013.","journal-title":"Front Immunol"},{"issue":"5","key":"8566_CR45","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","volume":"45","author":"L Short","year":"2024","unstructured":"Short L, Holt RA, Cullis PR, Evgin L. Direct in vivo CAR T cell engineering. Trends Pharmacological Sci. 2024;45(5):406\u201318. https:\/\/doi.org\/10.1016\/j.tips.2024.03.004.","journal-title":"Trends Pharmacological Sci"},{"issue":"6","key":"8566_CR46","doi-asserted-by":"publisher","first-page":"101612","DOI":"10.1016\/j.gendis.2025.101612","volume":"12","author":"Z Song","year":"2025","unstructured":"Song Z, Zhou Y, Wang B, Geng Y, Tang G, Wang Y, et al. In vivo production of CAR T cell: opportunities and challenges. Genes & Dis. 2025;12(6):101612. https:\/\/doi.org\/10.1016\/j.gendis.2025.101612.","journal-title":"Genes & Dis"},{"issue":"2","key":"8566_CR47","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","volume":"25","author":"A Bot","year":"2026","unstructured":"Bot A, Scharenberg A, Friedman K, Guey L, Hofmeister R, Andorko JI, et al. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat Rev Drug Discov. 2026;25(2):116\u201337. https:\/\/doi.org\/10.1038\/s41573-025-01291-5.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08566-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08566-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08566-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T07:07:58Z","timestamp":1788160078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08566-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8566"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08566-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with applicable institutional, national, and international guidelines for Good Manufacturing Practice (GMP), Advanced Therapy Medicinal Products (ATMPs), and biosafety regulations. The GMP manufacturing platform, including lentiviral vector production and associated quality control procedures, was established under the regulatory oversight and certification of the Spanish Agency of Medicines and Medical Devices (AEMPS). All activities involving genetically modified organisms were performed under the corresponding authorizations from the competent Spanish authorities. As this work focused on process development, manufacturing validation, and quality control platform implementation, no direct human participant enrolment was involved in the present study. Clinical application of the resulting CAR T-cell product (CARTemis-1) is conducted separately approved clinical trial protocols in accordance with relevant ethical and regulatory approvals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"all authors consent for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.A-P-S serves as an advisor or consultant for Novartis, Janssen, Roche, Jazz Pharmaceuticals, Amgen, and Gilead Sciences; has received research funding from Novartis, Janssen, Pfizer, Roche, and Takeda; has received travel support from Roche, Gilead Sciences, and Janssen; and holds patents, royalties, or other intellectual property with Entourage Bioscience related to cannabinoid derivatives. E.G-G has acted as a consultant for Cellgene and GLS, and received travel grants and\/or speaker fees from Cellgene, Amgen, and Janssen. E.G-G is also a co-inventor on a patent application filed by the University of W\u00fcrzburg, Germany, and licensed to T-CURX GmbH, Germany, (WO2021\/209498 A1).","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1119"}}